ARROWHEAD PHARMACEUTICALS, INC. Research and Development in Process
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Research and Development in Process of $15.85 million for the 131-month period ending 2014-03-31, per its 10-Q filed 2014-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2014-05-06
- 2014-03-31: .
- 2013-12-31: .
- 2013-09-30: .
- 2013-06-30: .
| Period end | Research and Development in Process 98 month | Research and Development in Process 101 month | Research and Development in Process 104 month | Research and Development in Process 107 month | Research and Development in Process 110 month | Research and Development in Process 113 month | Research and Development in Process 116 month | Research and Development in Process 119 month | Research and Development in Process 122 month | Research and Development in Process 125 month | Research and Development in Process 128 month | Research and Development in Process 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $15.85M 10-Q · filed 2014-05-06 | |||||||||||
| 2013-12-31 | $15.85M 10-Q · filed 2014-02-04 | |||||||||||
| 2013-09-30 | $15.85M 10-K · filed 2013-12-18 | |||||||||||
| 2013-06-30 | $15.85M 10-Q · filed 2013-08-07 | |||||||||||
| 2013-03-31 | $15.85M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $15.85M 10-Q · filed 2013-02-13 | |||||||||||
| 2012-09-30 | $15.85M 10-K · filed 2012-12-28 | |||||||||||
| 2012-06-30 | $2.69M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | $2.69M 10-Q · filed 2012-05-08 | |||||||||||
| 2011-12-31 | $2.69M 10-Q · filed 2012-02-09 | |||||||||||
| 2011-09-30 | $2.69M 10-Q · filed 2012-08-13 | |||||||||||
| 2011-06-30 | $2.69M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |